Jaguar Health, Inc. (JAGX) Earnings Call Transcript
August 19, 2026
Earnings Call Speaker Segments
Thanks a lot, Paul. Hi everyone, and I appreciate you being here on our investor webcast today. I'm Lisa Conte — you already heard that — and I serve as Founder, President and CEO of Jaguar Health along with our fully owned subsidiary, Napo Pharmaceuticals. I also hold the Chairman role at our Italian subsidiary, Napo Therapeutics. Typically, I'll refer to Jaguar and Napo as if they're the same when talking about our company. Once I finish, Carol Lizak, our CFO, will walk through a summary of the financial highlights from the second quarter of 2026. Today's webcast centers on transformation, near-term catalysts and sharp strategic focus. Lots of you tracking this company will remember that in January of this year, January 2026, we closed a transformative deal — signing a U.S. Commercial out-license agreement with Future Pak covering Mytesi, which is the brand name for our FDA-approved tablet formulation of crofelemer for adults living with HIV AIDS and diarrhea, and also covering the brand name Canalevia-CA1, our conditionally approved crofelemer formulation for dogs with chemotherapy-induced diarrhea. Our strategic decision to out-license Mytesi to Future Pak came about for two reasons: first, they had just acquired Theratechnologies, an HIV-focused commercial company whose U.S. commercial effort is more than 4x Jaguar's, including two other HIV-related and relevant products. Second, it fulfilled our strategic plan of bringing in meaningful nondilutive dollars to help fund our sharp development focus on the pivotal stage program for our novel proprietary powder for oral solution formulation of crofelemer — so a different product of crofelemer, same active ingredient, a different product, different formulation — for rare Intestinal Failure indications, and rare here means we hold orphan drug designation for the Intestinal Failure indications in the United States and Europe. These days we are fully a rare disease GI company, with 100% of our human development efforts sharply and strategically focused on a rare disease program. Identifying a development and commercialization partner for this program remains our ultimate strategy. For some perspective: the Future Pak out-license brought $18 million upfront, primarily for the U.S. HIV market, where peak annual market opportunity might reach $50 million to $70 million annually. Intestinal Failure, by contrast, has an annual peak market opportunity assessed by third parties at approximately $8 billion. Let me comment briefly on two recent third-party transactions of interest: in June of 2026, Eli Lilly licensed Hanmi's Phase II GLP agonist GLP-2 — not GLP-1, not the weight loss thing, GLP-2 — which targets an Intestinal Failure Short Bowel Syndrome for — in fact, for the rare disease of Short Bowel Syndrome, a deal worth up to $1.26 billion, including $75 million upfront and up to $1.185 billion in milestones plus royalties; then in August 2026, only a week ago, Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront, plus up to $500 million in milestones, a potential $1.32 billion deal centered on a proof-of-concept clinical stage. This is a KCNT1 inhibitor aimed at an ultra-rare genetic form of epilepsy, and it's strikingly similar to the program we already have underway in intestinal failure. Because of that, our current focus is on finding a possible partner for rare disease indications whose worldwide market is believed to sit in the multibillions, with comparable deals showing proof of concept at a stage earlier than where we stand now. When it comes to our Intestinal Failure development program, the value driver in the near term is our lead target indication, Pediatric Microvillus Inclusion Disease. I'll be calling that MVID — an ultra-rare disorder, ultra-rare, with no approved therapies and a lethal natural history. We've begun an ongoing clinical path toward a possible clinical package that should be finalized by the close of 2026. That means we're only a couple of months out, plus an NDA submission in the middle of next year, 2027. Short Bowel Syndrome, which you'll hear me call SBS, together with Intestinal Failure, or SBS-IF, is a bigger follow-on indication drawing on the identical dosage form and physiological mechanism as Intestinal Failure in MVID patients, and it remains a rare orphan indication. Our Intestinal Failure program amounts to a blockbuster global market opportunity when it comes to tackling this catastrophic unmet medical need among patients, and blockbuster in terms of the beneficial effect on morbidity, mortality and the cost borne by the health care system, as well as the financial return opportunity for all stakeholders, including, naturally, shareholders. That return opportunity matters especially to a possible corporate partner. As I noted, the global market for Short Bowel Syndrome with Intestinal Failure is projected to hit roughly $8 billion in 2033, based on third-party market research. And that same — a separate third party, but that third party puts the value of the worldwide MVID marketplace, an ultra-rare indication, at more than $1 billion in 2033, and for it there are no treatments and nothing in clinical development besides crofelemer. So let me take a moment to describe how catastrophic intestinal failure is for patients and what that means for the caregiving community around them, which takes in the health care professionals, the family members and others. Intestinal failure — it's a debilitating condition that frequently means patients must get life-sustaining fluids, electrolytes, nutritions via IV administration — IV administration for the nutrients of life, all of which falls under something called TPN, Total Parenteral Nutrition with supplemental intravenous fluids. And overall TPN, the fluids, it's called PN parenteral support, IV support for your nutrients of life. A lot of intestinal failure patients need parenteral support, IV nutrition as much as seven days a week and at times for 20 hours a day or more. So clearly, this is a catastrophic situation for the patient, health care, quality of life. Although it is supportive, it's palliative and it is required for life sustenance, it's also tied to serious complications, among them liver and kidney toxicities. Compromised cognitive function can negatively affect growth and survival. And the cost is meaningful. The yearly expense in the US for one patient is roughly $500,000, I believe. But when you factor in what it costs the healthcare system once complications arise — imagine needing intravenous feeding daily — those infection-related issues and the difficulty of maintaining proper nutrient balance can push past $1 million annually for each patient. And on top of that, there's the danger of death. MVID is something you're born with, a congenital condition. The baby arrives with severe diarrhea, can't take in the nutrients needed for life, and frequently these infants pass away very quickly. That's the outcome when no immediate diagnosis is made. Should a diagnosis happen, then for the remainder of that person's existence they'll require parenteral support — once more, 7 days each week, 20 hours per day. What matters most to us as we try to deliver adjunctive therapy for these individuals is cutting down how long they depend on parenteral support. Lessening that reliance could greatly affect the enormous toxicities and comorbidities that shorten these patients' lives — parental support that keeps them alive yet shortens life because of the toxicities tied to it. Thus the goal within clinical development is the chance to lower parental support by as little as 10% to 15%.
Thinking about how this affects the patient's day-to-day life, most of the parental nutrition could be given at night while they're sleeping. That way they keep a decent quality of life, can still go to school when they're awake, and they wouldn't need an IV attached to them just to do normal everyday things. So remember that range: 10% to 15%. Back in June, we shared some really important findings at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology and Nutrition Meeting, known as ESPGHAN, which took place in Lille, France. During ESPGHAN, we shared findings from the liquid oral version of crofelemer — a formulation made specifically for intestinal failure — showing meaningful decreases in PS, and especially in PS, since these are pediatric intestinal failure patients whose growth had normalized relative to body weight. They received the drug orally for over a year, and there were no notable clinical or lab abnormalities. Essentially, the safety profile was very clean. For one MVID patient, weekly parenteral support needs, when normalized to body weight, dropped by as much as 48%. Keep in mind the 10% to 15% figure I brought up earlier — here we're seeing up to 48% after more than 12 months of crofelemer treatment. For the two patients with SBS-IF, the amount of PS they needed, adjusted for body weight, dropped by as much as 40%, and that was also maintained across more than twelve months of treatment. That outcome is remarkable. Words fall short when trying to convey just how much this matters in a clinical setting. As I noted earlier, a reduction of even 10% would have counted as clinically meaningful. One more finding really jumped out: after about three months of therapy, those patients were instructed by the study protocol to discontinue Crofelemer — and their symptoms returned almost immediately, which meant they had to start the drug again. When a trial is designed this way, it becomes one of the strongest possible demonstrations that a product truly delivers a benefit. These same people have by now stayed on treatment for more than twelve months, and our expectation is that they will remain on crofelemer for the remainder of their lives — something we're deeply proud to supply. Across all of our intestinal failure patients, and in every individual who has received crofelemer, we've seen zero safety concerns tied to the drug. That picture lines up closely with what's been observed for crofelemer across thousands of patients enrolled in trials for other conditions. It's worth remembering that the FDA grants approval based on a drug's benefit-risk ratio. If risk drops to zero, then the benefit continues forever. On top of that, we now have one more MVID patient receiving oral crofelemer through compassionate use, under an expanded access program authorized by the FDA, and data on both safety and efficacy from that case was likewise shared at the same ESPGHAN gathering held this June in Lille. Here's a case that stands out: a baby got an MVID diagnosis right at birth, but the FDA's enrollment rules for Napo's trial meant the infant was too young to be included. Expanded access to crofelemer changed that — the child started on the drug at three months of age, or just shy of it. Today that child has reached one year, is thriving, maintains a busy Instagram presence, and lands close to the 30% point on the growth curve. What could have been a heartbreaking diagnosis with a deadly natural progression has instead become a story of a child who is flourishing. This patient is now taking a little food orally, and the amount of parenteral support has been reduced — it went from 22 hours down to 18 hours, and that change happened within the first year of life. So we continue to be committed to providing our investigational crofelemer formulation, which is novel, whenever a physician or caregiver determines it is medically needed for patients enrolled in these expanded access programs; the purpose of those programs is to lessen the consequences that come from MVID progressing in pediatric patients. Taking part in expanded access programs lets us build relationships with this extremely small community of physicians, institutions, and patients who deal with intestinal failure, especially intestinal failure tied to the ultra-rare disease MVID, before the product wins approval and reaches the market commercially. Meanwhile, a blinded pediatric trial is underway to evaluate the safety and efficacy of this crofelemer formulation in patients with intestinal failure resulting from MVID. In addition, there's a separate blinded study—unlike the unblinded, treatment-only results I just referred to, which we can see. Enrollment is now complete in this pivotal randomized, double-blind, placebo-controlled trial, and it is actively conducting at sites across the United States, Italy, and the UAE. To support our planned new drug application submission drawing on data from patients in this trial, we filed an amendment and obtained FDA clearance for a treatment-only extension phase of the study. So once the blinded portion concludes, patients may keep going in the treatment-only extension if a safety committee — on which we do not sit, and which stays blinded along with the treating physician and the family — deems it relevant for the patients. Every single patient was judged relevant to enter the treatment-only extension phase. The initial group of MVID patients has now entered the treatment-only extension. Along with those individuals, we have the early access patients we've reserved and previously presented — for example, at ESPGHAN — plus the investigator-initiated trial in the UAE. Given all of this, we're talking about the possibility of submitting a new drug application for crofelemer in MVID, an ultra-rare condition where we hold orphan designation across the United States and Europe, and which involves essentially a single-digit number of patients. If you tally up everyone in our blinded study together with the MVID individuals in expanded access and investigator-initiated protocols, we estimate that about 4% of the patient population is being treated by us. So even though filing with a single-digit patient count might seem outdated, it carries relevance for other conditions when you consider what share of affected patients we're actually treating. Our confidence is high, and we're deeply committed to securing crofelemer's approval for every MVID patient as quickly as we possibly can; so on the timing question, our aim is to get sufficient enrollment in the treatment-only blinded trial. As I noted earlier, every participant from the placebo-controlled portion of the study was eligible to enroll in the treatment-only arm. So we need adequate patient numbers by Q4 of this year in order to submit for breakthrough therapy designation in the United States. Should breakthrough therapy designation be awarded, that would open the door for a review following our new drug application submission of possibly only 4 months after the NDA goes in. We expect the clinical package needed for the NDA to be complete by the close of 2026, with the NDA itself being submitted during Q2 — late in Q2 of 2027. So assuming we receive breakthrough designation, U.S. approval could come by the close of 2027 for MVID. Europe would follow somewhat later. That would happen in 2028, reflecting the European Medicines Agency and certain of its requirements around reimbursement along with risk-benefit analysis. Intestinal failure in MVID mirrors the same circumstances as intestinal failure in Short Bowel Syndrome.
When it comes to Short Bowel Syndrome, or patients dealing with intestinal failure, the issue is that they can't take in the nutrients needed for life, simply because their bowel is too short. The surface area available is insufficient. A typical intestine measures somewhere around 20 to 25 feet, while in SBS-IF it might be 5 feet or even less — so the surface area is genuinely inadequate. These individuals may also wind up requiring parenteral support for as much as 20 hours per day, every day of the week. On top of that, they experience the very same comorbidities and the very same devastating toxicities associated with parenteral support that MVID patients endure. Right now we're running a Phase II randomized, double-blind, placebo-controlled trial using the identical formulation — the lipid formulation of crofelemer — in adult SBS-IF patients, and it's being conducted across multiple sites in Germany and Italy. This remains an orphan indication, and we hold orphan designation in both the U.S. and Europe for Short Bowel Syndrome, exactly as we do for MVID in the U.S. and Europe. Even though the patient population is bigger than MVID's, MVID comes from congenital abnormalities, whereas SBS may stem from congenital abnormalities, surgical resection tied to conditions such as Crohn's disease, ischemia, surgical resection because of cancer — which accounts for roughly 1/3 of patients — or trauma accidents. Adult and pediatric SBS-IF patients deal with chronic reliance on parenteral support because, once again, their intestines lack sufficient absorptive surface area; within the United States, that population numbers around 12,500; we're aiming for the NDA filing of crofelemer for MVID in mid-2027, and we anticipate that this NDA filing will line up with when results become available from the Phase II blinded study for SBS. Since our MVID development program uses the same formulation, this plan gives us CMC — Chemistry Manufacturing Controls — essentially the manufacturing stepping stone toward our intended pathway for eventual approval of crofelemer for SBS following MVID, and that will come years after MVID. However, the safety profile would be identical, and the manufacturing would be identical; so to — looking at the competitive landscape, nothing exists for MVID. Nothing is out there in development, and nothing exists for these patients; in SBS, one product is approved, and it takes a GLP-2 approach — not GLP-1, that's the weight loss one. GLP-2 is basically a growth hormone. What GLP-2 does is try to grow the intestine somewhat, so that parenteral support can be cut by 10% to 15%. If you recall, those figures are regarded as clinically irrelevant. Once again, we obliterated those with the 40% to 45% in MVID. GLP-2 growth hormone for SBS is not standard of care. It carries many side effects, and it is a growth hormone. You can't administer a growth hormone. For instance, you don't want to promote growth in cancer patients or anyone in a hyperproliferative abnormal situation. And that represents about 1/3 of SBS patients. Even so, what GLP-2 has accomplished is establishing a business model and a regulatory approval benchmark. GLP-2s get reimbursed at roughly $0.5 million annually per patient in the United States. Our goal is for crofelemer to be recognized as the go-to treatment for intestinal failure, covering both MVID and SBS. GLP-2s only get used by roughly 5% to 7% of patients, and they aren't suitable for lifelong chronic use, while crofelemer is. Crofelemer might also be given alongside GLP-2s. That makes crofelemer a genuinely paradigm-shifting chance to boost quality of life, possibly lengthen how long patients live, deliver meaningful physiological advantages, and lower possible toxicity; so the thing I've been discussing in our rare disease program, our test failure program, is crofelemer. Crofelemer serves as the active ingredient in Mytesi, yet our Intestinal Failure program isn't Mytesi. It involves a separate formulation, a separate product. Mytesi comes as a pill — in intestinal failure, a pill would simply pass straight through the patient, given high throughput and high transfer times, ending up in the toilicle. The oral liquid formulation, a highly concentrated lyophilized version of crofelemer, is non-growth hormone and represents a drug candidate intended for use as adjunctive therapy to parenteral support via a first-in-class physiological mechanism of action, cutting liquid stool output and thus lowering parenteral support requirements along with the related toxicity tied to that. Another key point: crofelemer is classified as an antisecretory, a first-in-class antisecretory drug; it isn't an anti-diarrheal. It acts locally on the intestinal clonidine channel, and normalization lessens chloride-driven fluid buildup in the intestines. This is getting somewhat technical, but the result is a decrease in electrolyte and fluid losses plus matching parenteral support reductions, which stands as the clinically relevant endpoint in both MVID and Short Bowel Syndrome Intestinal Failure; we've shown we can execute and finalize a significant non-dilutive business development deal in January through the Future Pak deal, as I noted. We received — we were given $16 million in non-dilutive capital in January when the agreement closed; we met certain post-closing conditions and got an extra non-dilutive $2 million, which formed part of the upfront fee from Future Pak; we remain the manufacturer of crofelemer for Mytesi and the Canalevia formulations for Future Pak under the deal's terms, and that happens at a profit. So it's a profit center for us. We manufacture in a centralized way. And under the agreement's terms, we may receive as much as another $17 million through additional milestone payments, future payments, once again non-dilutive. The intestinal failure market we're now keenly targeting is believed to be around 100x bigger than the HIV diarrhea market. Alright, using those figures I mentioned—$18 million paid upfront plus $17 million in further milestone payments—what we're looking at is a market opportunity that's 100x bigger. Given the clinical proof-of-concept results we already have, along with the clinical and regulatory milestones that are happening in the very near term, we feel confident about hitting our business development objectives for the Intestinal Failure program. That will let us push this opportunity forward and bring in substantial, significant, valuable non-dilutive capital that matches the size of the market, the serious unmet medical need, and is driven above all by the benefit and the benefit-risk—with risk being almost 0—that we deliver to patients who have no other treatment option. Just quickly, I should note that human health is, of course, the main focus of our business, and our rare disease program represents 100% of our human focus. We do have a small animal health business, and we're happy to share that we recently announced plans for the anticipated commercial launch, happening very, very soon, of a product named Neonorm Dog. It's a new addition to Jaguar's nonprescription Neonorm franchise for companion animals. Neonorm Dog is made to give dog owners access to a plant-based, non-prescription product meant to support normal stool consistency and GI fluid balance in dogs; it also works through an antisecretory mechanism of action. What we're doing is building on the relationships we established while promoting and educating around Canalevia-CA1 before it was licensed to Future Pak. Canalevia-CA1, again, was our FDA conditionally approved prescription drug for treating chemotherapy-induced diarrhea in dogs.
Right now, under the Neonorm franchise, we also have additional Neononorm items — those are non-prescription offerings made for foals as well as calves — plus plant-based items designed to help maintain proper hydration and bowel health in pre-weaned foals and calves. A large number of the veterinarians we talked to while we were doing education and promotion related to chemotherapy-induced diarrhea told us there was a significant unmet need when it comes to handling general watery diarrhea in dogs, whatever the cause may be. And today, with Neonorm Dog, we'll be able to give them something, as well as give doggy parents something, since Neonorm Dog will be easily available through online and animal health retail channels, not solely from their vet, and that includes Amazon and Chewy, which is a truly outstanding venue for animal health products. Given all of that, you can tell how excited and how enthusiastic we are about what we're doing, and I'll now pass the discussion to Carol Lizak, our CFO, so she can recap the financial highlights from the second quarter of 2026; and before I hand it to her, I just want to remind everyone that for many years, we sold Mytesi ultimately into the distributors and had a sales force promoting directly to the physicians who prescribe to patients. Currently, we supply Future Pak. Because of that, the effect on the sales and revenue figures we report is quite different. Carol, I'll turn it over to you.
Good afternoon, Lisa, and thanks to everyone joining our webcast today. I'll start by reviewing the financials for the second quarter of 2026. On license and grant revenue, as Lisa noted, Jaguar signed a U.S. commercial licensing agreement with Future Pak in January 2026, making Future Pak the exclusive U.S. marketer of the company's Mytesi and Canalevia-CA1 products. The initial $16 million upfront payment, plus the $3 million payment for early termination of the buyback option under that agreement, was recognized as license revenue by the company in the first quarter of 2026. As announced in August 2026, Jaguar has met the closing conditions needed to receive the non-dilutive $2 million holdback portion of the upfront fee from Future Pak. Napo continues to manufacture crofelemer and Mytesi and supplies the product to Future Pak on cost plus terms. In addition, the company recognized $43,000 in license fees in the second quarter of 2026 from a securities purchase agreement with a European partner, which a binding term sheet supported. Roughly $43,000 in license fees was recognized in each quarter of 2025 under this agreement. As of June 30, 2026, total deferred revenue tied to this contract comes to $468,000. Federal grant revenue recognized in the second quarter of 2026 for the clinical trial study on treating Chemotherapy-Induced Diarrhea, or CID, in dogs was $25,520, versus none last year. Turning to prescription product revenue net, total net revenue for the company's prescription products — Mytesi, Gelclair and Canalevia-CA1 — came to approximately $1.2 million in the second quarter of 2026, driven mainly by Mytesi sales at cost plus to Future Pak; in January 2026, Jaguar entered a royalty-free license agreement with Future Pak. Again, under this agreement, all revenues generated in the United States from Mytesi and Canalevia-CA1 effective from January 12, 2026, go to Future Pak. Future Pak is privately held and does not report Mytesi sales. Versus the second quarter of 2025, the number of Mytesi bottles the company sold in the second quarter of 2026 rose significantly, and commercial costs fell substantially. The choice to enter a commercial license agreement with Future Pak fits Jaguar's strategic focus on advancing development of its powder for oral solution formulation of crofelemer for rare disease indications tied to intestinal failure in humans. Total net revenue for the company's prescription products in the second quarter of 2026 reflects a decrease of approximately 2% versus the first quarter of 2026, when total net revenue for prescription products was approximately $1.2 million. In addition, prescription products net revenue dropped by 60% versus the second quarter of 2025, when total revenues were about $2.9 million. The operating loss did go down by roughly $400,000, moving to a loss of $7.6 million for the quarter that closed June 30, 2026, compared with a loss of $8 million for the quarter that closed June 30, 2025. What drove that was mainly a $1.7 million drop in product net revenue, though it got offset by roughly $2.1 million less in operating expenses, mostly tied to the Future Pak licensing agreement. As for non-GAAP recurring EBITDA, the second quarters of 2026 and 2025 came in at net losses of about $8.4 million and $7.9 million, respectively. Net loss attributable to common shareholders rose by roughly $2.3 million, from a loss of $10.4 million for the quarter that closed June 30, 2025, to a loss of $12.7 million for the quarter that closed June 30, 2026; beyond the operating loss, interest expense climbed by $176,000, from $15,000 of interest income for the quarter that closed June 30, 2025, to about $161,000 for the quarter that closed June 30, 2026, because of interest expenses accrued on notes. The fair value of financial and hybrid instruments designated as FVO, or Fair Value Option, rose by about $900,000, from a loss of $1.1 million for the quarter that closed June 30, 2025, to a loss of $1.9 million for the quarter that closed June 30, 2026, and once again, that was mostly from fair value adjustments in liability classified warrants and notes payable designated as FVO. Loss on extinguishment of debt rose by $1.7 million, from a loss of $1.8 million for the quarter that closed June 30, 2025, to a loss of $3.5 million during the three months ended June 30, 2026, because of significant modifications to qualify for extinguishment accounting, with none recorded in the same period in 2025. Well, that wraps up my recap of high-level financials for the second quarter of 2026. I will now hand the discussion back to Lisa. Thank you.
Appreciate that, Carol. We'll keep this brief. To sum up, our Intestinal Failure program is going to keep delivering clinical proof-of-concept milestones, and it's currently the focus of business development talks that could generate significant non-dilutive dollars from prospective licensee partners. A key point: crofelemer stands as the first and only oral prescription drug the FDA has approved under botanical guidance, and that gives us what amounts to a perpetual IP intestinal protection shield — an exclusivity shield — since there's no realistic route for a generic to reach the market. So while we hold a very strong, wide-ranging IP patent strategy, as any pharmaceutical company would — it's simply the cost of playing in this space — we have roughly 185 issued patents. In effect, we hold exclusivity forever, to infinity and beyond, which carries a lot of weight when you're running terminal value calculations alongside, say, prospective commercial partners. You avoid that patent cliff you so frequently hear and read about at other companies. So, as I'm sure you can gather, every member of the Jaguar, Napo, Napo Therapeutics family is completely engaged, fully energized, and enthusiastic about the many near-term catalysts we expect on the regulatory and clinical fronts for crofelemer, and on the business front too — all of which we consider significant, extremely value-enhancing, and possibly transformative for patients and for diseases where medical needs remain entirely unmet. Everything we do across Jaguar, Napo, and Napo Therapeutics is gratifying, and our work to tackle these genuinely devastating rare intestinal failure diseases has brought us satisfaction on a whole different level. That wraps up our webcast for today. Many thanks for being with us, and we'll see you next quarter.
That wraps up the call for today. Thanks once more for joining us. At this point, you're free to hang up your lines.
For developers and AI pipelines
Programmatic access to Jaguar Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.